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ABSTRACT 
Omeprazole is a proton pump inhibitor, antacid drug. It is categorized as class II in BCS system of classification of drugs. Omeprazole inhibits 
the H(+)-K(-) ATPase in the proton pump of gastric parietal cells and highly effective inhibitor of gastric acid secretion. Floating tablet is 
nowadays considered as one of the best method to enhance the retention time of tablet in stomach. To get a better dissolution rate, the 
retention time of Omeprazole is enhanced by the floating technique. The aim of the work is to formulate the floating tablet of Omeprazole and 
evaluation of tablets invitro performance. The floating tablets are prepared by using two different polymers; HPMC K15, HPMC K100. Wet 
granulation method was used to prepare tablet. The polymers added in different ratios. The increasing concentration of polymers is responsible 
for enhancement of drug content and percent yield due to increase in the swallability of polymer.Invitro drug release study w as performed 
using United State Pharmacopoeia (USP) type II dissolution test apparatus employing paddle stirrer at 50 rpm using 900ml of 0.1 N HCL buffer 
maintained at 37⁰C±0.5⁰C as the dissolution medium. The FTIR, DSC studies of Omeprazole floating tablet indicated the phase inversion of 
Omeprazole from crystalline to amorphous form. The F3 formulation show increased drug release as compare to pure drug in 24 hrs. It can be 
concluded that the floating tablet of Omeprazole prepared with mixture of HPMC K15 and HPMC K100 has greater retention time than pure 
drug and marketed formulation.   
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INTRODUCTION 
The main aim of drug therapy is to provide therapeutic 
amount of drug to desired site in body, and to quickly 
achieve and maintain desired drug concentration. The most 
important two aspects of drug delivery are called spatial 
placement and temporal delivery of drug. Spatial placement 
is related to targeting a drug to particular organ or tissue 
while temporal delivery refers to controlled rate of drug 
delivery to that specific organ or tissue.(1) 
Omeprazole 
Omeprazole is in a class of drugs called proton pump 
inhibitors (PPIs) which block the production of acid by the 
stomach. Other drugs in the same class include lansoprazole 
(Prevacid), rabeprazole (Aciphex) and pantoprazole 
(Protonix). Chemically, Omeprazole is very similar to these 
drugs. Proton pump inhibitors are used for the treatment of 
conditions such as stomach and duodenal ulcers, 
gastroesophageal reflux disease (GERD) and the Zollinger-
Ellison syndrome which all are caused by stomach acid. 
Omeprazole, like other proton-pump inhibitors, blocks the 
enzyme in the wall of the stomach that produces acid. By 
blocking the enzyme, the production of acid is decreased.2 
Granulation 
Granulation, the process of particle enlargement by 
agglomeration technique, is one of the most significant unit 
operations in the production of pharmaceutical dosage 
forms, mostly tablets and capsules. Granulation process 
transforms fine powders into free-flowing, dust-free 
granules that are easy to compress. and this allows the 
stomach and esophagus to heal. Granulation process can be 
divided into two types: Wet granulations that utilize a liquid 
in the process and dry granulation that requires no liquid 
among currently available technologies, spray drying, roller 
compaction, high shear mixing, and fluid bed granulation are 
worth of note. Obviously, the pharmaceutical granulation 
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techniques and technologies have improved over the years.3 
Optimization 
Optimization of a pharmaceutical process using design of 
experiments is traditional approach that involves changing 
one variable at a time. Optimization means determining best 
course of action among various alternatives available in 
decision making problem. Optimization is defined as the 
implementation of systemic approaches to achieve best 
combination of process or product characteristics under a 
given set of condition. Optimization approaches employing 
design of experiments have advantages like require fewer 
experiments to achieve an optimum formulation 
rectification quite easier, make problem tracing, reveal 
drug/ polymer interaction and comprehend the process to 
assist best formulation development and subsequent scale 
up .Optimization is a decision-making process in which 
decisions have to be taken which optimize one or more 
specified objectives under prescribed set of circumstances.4 
EXPERMENTAL WORK 
Material: 
Omeprazole was obtained as gift sample from Alwell 
Pharmaceuticals (Chandigarh, India). HPMC K15M and 
HPMC K100M were obtained as gift sample from USB 
Pharmaceuticals (Baddi). All other chemicals are provided 
by the institution. 
Preformulation Studies  
Preformulation testing is the first step in rational 
development of both active pharmaceutical  
Ingredient (API) and drug product. They influence:  
• Drug performance and development of an efficacious, 
stable and safe dosage form Drug candidate selection  
• Formulation components selection  
• The physicochemical parameters of new drug 
substance  
• Development of analytical method and  
• Drug and excipient compatibility.  
Drug characterization:  
Omeprazole was characterized by various tests of 
identification  
Determination of melting point  
Melting point of Omeprazole was determined by Capillary 
fusion method using Remi's melting point apparatus and 
DSC method was used to determine the melting point of 
Omeprazole as shown in fig 5.8-5.10. The point at which 
Omeprazole melts was recorded from the thermometer and 
compared with the literature value. 4 
λmax selection  
The stock solution (stock I) of Omeprazole (100 ug/ml) in 
0.1N HCI was prepared by dissolving Omeprazole (10 mg) in 
10 ml methanol and then final volume was made up to 100 
ml with 0.IN HCl, 1 ml of stock solution of Omeprazole was 
taken and diluted with 9 ml of 0.IN HCl to obtain 
concentration of 10μg/ml . Ten tablets (LOSEC 40) were 
weighed and powdered. Amount of powder equivalent to 
one tablet was weighed and transferred to 50 ml volumetric 
flask. 5 ml of methanol was added and the powder was 
dissolved by vigorous shaking. Final volume was made up to 
50 ml by adding 0.1N HCI to obtain a concentration of 200 
μg/ml. The solution was centrifuged and 5ml of the 
supernatant was taken and diluted with 5 ml of 0.IN HCI to 
obtain concentration of 100 μg/ml. 1 ml of this solution was 
further taken and final volume was made up to 10 ml using 
0.IN HCl to obtain 10μ/ml. Overlay spectrum of both the 
solutions (stock I and tablet test solution) were taken using 
UV spectrophotometer. The spectrum is presented in Fig 
5.2.5 
 Drug excipient interaction studies: 
Omeprazole, HPMC K15M , and HPMC K100M were 
physically mixed in ratio 1:1(100 mg each) by geometric 
mixing, filled in vial and kept at accelerated conditions, 
(40°C+2°C/75%RH±5%RH). The samples were taken out at 
predetermined time point (0, 1, 2, 3, 4 weeks) and then 
examined visually for any change in physical appearance. 
The data is shown in Table 5.1. The drug alone, excipient 
alone and physical mixture were taken and subjected to 
FTIR and  DSCstudies.6 
Fourier transform infrared spectroscopy  
IR spectroscopy is most powerful technique for fualitative 
compound identification. It gives information about the 
group present in the particular compound. FTIR 
transmission spectra of pure drug (Omeprazole), HPMC 
K15M, HPMC K100M, their physical mixture and optimized 
batch of floating tablet were recorded using a Perkin Elmer 
1600 FTIR spectrophotometer by Potassium Bromide (KBr) 
disc. Samples (0.5mg) were mixed with dry KBr and 
compressed into discs by applying a pressure of 7-10 
Newton's. IR spectrum of each sample was recorded in the 
scan range of 4000-400 cm. FTIR spectra of drug and 
polymer are shown in fig.5.3 - 5.5.7 
Differential scanning calorimetry  
Differential Scanning Calorimetry study of pure drug 
(Omeprazole), HPMC K15M, HPMC K100M, their physical 
mixture and optimized batch of Omeprazole were performed 
using METTLER differential scanning calorimeter. 
Accurately weighed Samples (2mg) were heated on 
aluminum pan and heated at a constant rate of 10°C/min 
under a nitrogen gas with flow of 40ml/min. Thermogram 
were recorded over the temperature range of 25 - 400°C, 
DSC of drug and polymers are shown in fig 5.8 to 5.10 8 
Preparation of calibration curve:  
For the estimation of Omeprazole in bulk drug and 
formulations. Among the various methods UV 
spectrophotometry is suitable for routine and quick 
estimation of Omeprazole in preformulation studies, 
formulation and dissolution samples Calibration curves for 
Omeprazole were using UV spectrophotometric method in 
various solvents.9 
Calibration curve of Omeprazole in 0.1N HCI 
Primary stock solution of Omeprazole (100ug/ml) in 0.1N 
HCI was prepared by dissolving Omeprazole (10 mg) in 
10ml of methanol and then final volume was made upto 100 
ml with 0.1N HCl. From this stock solution, the aliquots of 
0.2 ml, 0.4ml, 0.6 ml upto 1.2 ml were transferred to 10 ml 
volumetric flask and volume was made upto 10ml with 0.1N 
HCl. The dilutions were scanned in the wavelength range of 
200-400 nm to obtain λmax of Omeprazole in 0.1N HCl. The 
spectrum is present in Fig 5.13. All the samples were then 
analyzed at chosen λmax for their respective absorbance 
using UV spectrophotometer and the data is reported in 
Table 5.7 and calibration curve is also constructed as shown 
in Fig 5.13.10 
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Formulation and Evaluation Studies  
Preliminary studies: 
A preliminary assessment was conducted to properly 
develop wet granulation method for production of floating 
tablet. Various batches of floating tablets were prepared by 
varying the drug/polymer (D/P) ratio and the amount of 
magnesium stearate, amount of glidant are accurate. The 
composition of floating tablet is given in Table 5.9.11 
Preparation of floating tablet:  
Omeprazole (500mg) was mixed with required quantity of 
mixture of polyıner (HPMC KI5M, HPMC K100M), sodium 
bicarbonate and lactose in mortar for 5 min using 
spatula.Iso- propyl alcohol was added drop wise till suitable 
mass of granulation was obtained. The wet mass was 
granulated through sieve 40#.The granules were dried at 
room temperature 350 for 1 hr, and then blended with talc 
and magnesium stearate in the weight proportion as 
mention in table and compressed on 10-station rotary tablet 
compression machine using a 8 mm standard flat- face die 
punch set.12 
Evaluation Parameters: 
Preformulation studies:  
Preformulation study is defined as an investigation of the 
physical and chemical properties of drug substance alone 
and when combined with the excipients. The overall 
objective of preformulation testing is to generate 
information useful to the formulator in developing a stable 
and bioavailable dosage form that can be mass produced. 
The investigated preformulation parameters include angle of 
repose, bulk density/tapped density, pour density, Carr's 
compressibility index and Hausner ratio.13 
• Angle of repose: 
It is determined by allowing a powder (1.25 gm) to flow 
through a funnel and fall freely on to a surface. Further 
addition of powder is stopped as soon as the pile touches the 
tip of the funnel. A circle is drawn around the pile without 
disturbing it. The height and diameter of the resulting cone 
are measured as shown in fig 5.12. The same procedure is 
repeated three times and the average value is taken. Angle of 
repose is calculated by using the following equation: 13 
Tan θ = h/r 
Where, h = height of the powder cone; r=radius of the 
powder 
Table 1: Relationship between angles of reposes and 
flow property: 
Angle of Repose (Degrees) Flow 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
 Bulk Density : 
Method I, pass a quantity of material (1.25gm)sufficient to 
complete the test through a 1.00-mm (no. 18) screen to 
break up agglomerates that may have formed during storage 
into a dry 250-ml cylinder introduce, without compacting, 
approximately 100g of the test sample (M) weighed with 
0.1% accuracy. Method II, Select a sample mass having an 
untapped apparent volume of 150–250 ml. A 100-ml 
cylinder is used for apparent volumes between 50 and 100 
ml. Fill the cylinder carefully. Carefully level the powder 
without compacting, if necessary, and read the unsettled 
apparent volume (Vo) as shown in fig 5.12 Calculate the bulk 
density, in g/ml, using the formula, 14 
Bulk density (P) = M/V.  
 Tapped Density :  
Accurately weighed quantity of powder (1.25gm) was 
introduced into a measuring cylinder. Mechanically tap the 
cylinder containing the sample by raising the cylinder and 
allowing it to drop under its own weight using a suitable 
mechanical tapped density tester at a nominal rate of 300 
drops/min. Tap the cylinder 500 times and measure the 
tapped volume (Va). Repeat the operation for an additional 
750 tapping sand again measure the tapped volume as 
(Vb).as shown in fig. 5.12  
Since the difference between Vaand Vb was higher, repeat 
the tapings for an additional 1,250 times, and then the 
tapped density was calculated using the following formula15 
Tapped density = M/Vf 
Where, M = weight of the sample taken; Vf= final tapped 
volume.(93)  
• Carr's index : 
The compressibility index of granules can be determined 
using Carr's compressibility index, as shown in fig. 5.12 and 
was determined by the following formula:15 
Carr's index (%) = (Tapped density –Pour density)Tapped 
density * 100  
4.4.2: Post compression parameters: 
The prepared tablets were evaluated for quality control tests 
like weight variation, hardness, thickness, friability and 
content uniformity. Table 5.13, 5.14  
• Weight variation: Ten tablets were selected randomly 
of 500 mg from each batch and weighed individually, 
calculating the average weight and comparing the 
individual tablet weight to the average. From this, 
percentage weight difference was calculated and then 
checked for USP specifications as shown in fig 5.13.  
Table 2 Percentage deviation in weight variation.17 
Average weight of the tablet Percentage Deviation 
130 mg or less  
More than 130 or less than 
324mg More than 324 
10 
7.5 
5 
 
• Hardness and friability: Hardness of tablet was 
determined by Monsanto Hardness Tester. Ten tablets 
were randomly picked from each batch and analyzed 
for hardness. The mean and standard deviation were 
also calculated. Friability test was done by Roche 
Friabilator. Ten tablets were weighed and were 
subjected to the combined effect of attrition and shock 
by utilizing a plastic chamber that revolve at 25 rpm 
dropping the tablets at distance of 6 in. with each 
revolution. Operated for 100 revolutions, the tablets 
were de-dusted and reweighed. The percentage 
friability was calculated as shown in fig. 5.13. 16 
• Tablet Dimensions: Thickness and diameter of tablets 
were measured using a calibrated dial calliper. Three 
tablets of each formulation were picked randomly and 
dimensions determined. It is expressed in mm and 
standard deviation was also calculated 37°C +1°C. At 
regular 1-hr time intervals until 24 hrs, the floating 
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tablets were removed from beaker and the excess 
surface liquid was removed carefully using the tissue 
paper. The swollen floating tablets were then re-
weighed (Wt), and% swelling index (SI) was 
calculated.17 
• Content uniformity test: The Omeprazole floating 
tablets were tested for their drug content. Five tablets 
were finely powdered; quantities of the powder 
equivalent to 15 mg of Omeprazole were accurately 
weighed and transferred to a 100 ml of volumetric 
flask. The flask was filled with 0.1N HCL (pH 1.2 buffer) 
solution and mixed thoroughly. The solution was made 
up to volume and filtered. 10 ml of the resulting 
solution was diluted to 100 ml with 0.1N HCL and the 
absorbance of the resulting solution at 300 nm using a 
Shimadzu UV-visible spectrophotometer was 
measured. The linearity equation obtained from 
calibration curve was used for estimation of 
Omeprazole in the tablet formulations. 14 
• In vitro buoyancy studies (23). The in vitro buoyancy 
was determined by floating lag time. The tablets were 
placed in a 250 ml beaker, containing 200 ml of 0.1 N 
HCI. The time required for the tablet to rise to the 
surface and float was determined as Floating Lag Time 
(FLT) and the time period up to which the tablet 
remained buoyant is determined as Total Floating 
Time (TFT) as shown in Table 5.1418 
In Vitro Dissolution Study19 
In vitro drug release study of floating tablet was carried out 
using USP type I dissolution apparatus. The baskets were 
covered by a piece of muslin cloth to prevent escape of the 
tablet to the release media. Tablet equivalent to 10 mg of 
Omeprazole was used in the dissolution study. The test were 
carried out in 0.1N HCI (900 ml) maintained at 37+0.5°C and 
stirring at 50 rpm. 10ml sample was withdrawn at regular 
time interval, and the same amount of fresh dissolution 
medium was replaced into dissolution vessel. The collected 
aliquots were analyzed spectrophotometrically at 300 nm 
respectively for their absorbance. Using calibration curves 
developed in respective media concentrations were 
calculated. To take into account the loss of drug in aliquot 
replaced the correction factor was used as shown in 
Equation given below.  
       
  
  
∑   
    
   
(
  
     
)               
Where, Ci = corrected absorbance, Vs = sample of dissolution 
media withdrawn, Vt = Total volume of dissolution media.  
Dissolution release profiles were plotted with percentage 
drug released at different time intervals as shown in Fig.5.14 
and the data is shown in Table 5.11.  
Kinetics Modeling of Drug Dissolution Profiles20 
To analysis the in vitro release data various kinetic models 
were used to describe the release kinetic. The dissolution 
profile of the all formulations was fitted to higuchi and 
Korsmeyer – Peppa’s model to ascertain the kinetic 
modeling of the drug release and mechanism of drug release. 
Zero Oder kinetics (Constant rate process) 
Drug dissolution from pharmaceutical dosage forms that do 
not disaggregate and release the drug slowly can be 
represented by following equation. 
                                         Ft= Kot 
Where ft is the fraction of drug dissolved in time t and Ko is 
zero order release constant. 
Pharmaceutical dosage form following this profile release 
the same amount of drug by unit of time and this is ideal 
method of drug release in order to achieve a 
pharmacological prolonged action. The following relation 
can in a simple way express this model. 
Qt= Qo + Kot 
Where, Qt is the amount o drug dissolved in time t, Qo is 
initial amount of drug in solution and Ko is zero order 
release rate constant. Most of the time Qo = 0. 
Application: This relationship can be used to describe the 
drug dissolution of several types of modified release 
pharmaceutical dosage forms, as in the case of some 
transdermal systems, as well as matrix tablets with low 
soluble drugs in coated forms, osmotic systems, etc. 
 First order kinetics (Linear kinetics): 
Rate is directly proportional to the concentration, of drug 
undergoing reaction i.e. greater the concentration, faster the 
reaction. The drug dissolution study was first proposed by 
Gibaldi and Feldman in 1967. The following relation in a 
simple way can be expressed as 
In (Qt/Qo) = K1t 
or in decimal logarithm. 
                                       Log Qt= log Qo- K1t/2.303 
Where, Q1 is amount of drug dissolved in the time t, Qo is 
initial amount of drug in solution and K1 is first order 
release rate constant. In this way a graphic of decimal 
logarithm of the release amount of drug versus time will be 
linear. 
Application: This relationship can be used to describe the 
drug dissolution in pharmaceutical 
dosage forms such as those containing water-soluble drugs 
in porous matrices. 
Higuchi model: 
Higuchi described the release of drug insoluble matrix as a 
square root of time dependent processes based on Fickian 
diffusion. A large number of modified release dosage form 
contain some sort of matrix system. In such instance, the 
drug dissolved from the matrix. The dissolution pattern of 
the drug is dictated by water penetration rate (diffusion 
controlled). In higuchi model, a plot of % drug release versus 
square root of time is linear. 
                                          Q= Kh t1/2 
Where, Kh is constant, t is time. 
Application: This relationship can be used to describe the 
drug dissolution from several types of modified release 
pharmaceutical dosage forms, as in the case of some 
transdermal systems and matrix tablets with water soluble 
drugs. 
Korsmeyer- Peppas model: 
To find the mechanism of drug release, drug release data 
was fitted in Korsmeyer –Peppas model, log of % cumulative 
drug release versus log of time. 
Mt/M∞= Ktn 
Where, Mt/M∞ is fraction of drug released at time t and K is 
rate constant, n is release exponent. 
Kaushal et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):679-687 
ISSN: 2250-1177                                                                                   [683]                                                                                     CODEN (USA): JDDTAO 
RESULTS AND DISCUSSION 
Preformulation Studies:  
 Drug characterization: 
Identity of drug was proved by various tests conducted for 
its characterization as shown below:  
• Determination of melting point: Melting point of 
Omeprazole as determined by capillary fusion method 
was 182°C and the DSC thermogram also showed a 
sharp endothermic peak at 182.6°C that corresponds 
to its melting point. Melting point obtained by both the 
methods was close to the value reported in Merck 
index 1996 i.e. 182 -182.8 °C. This proved the identity 
of the drug. 
• λmax selection: The UV spectrum of Omeprazole in 
0.1N HCL has one maximum absorption band at 300 
nm. As a result 300 nm was selected for quantitative 
analysis to prevent excipient interference.  
•  
 
Fig 1 Representative λmaxof 10μg/ml Omeprazole stock 
solution II. 
 
Fig: 2 Overlay spectrum of 10μg/ml Omeprazole stock 
solution II. 
 
Fig 3: Calibration curve of Omeprazole in 0.1N HCI. 
 
Drug Excipient Interaction Studies  
Omeprazole was white in color and HPMC K15M and HPMC 
K100M were also white. When the drug was blended with 
polymer the appearance of the physical mixture was white. 
When the physical mixture was stored at accelerated 
condition (40°C+2°C/75%RH±5%RH), no significant 
changes were observed in the physical characteristics of 
drug in the presence of polymer in a closed vial as shown in 
Table 5.1.  
 
Table 3: Result of physical compatibility of Omeprazole with polymer at accelerated storage condition 
(40°C+2°C/75%RH±5%RH). 
Drug/ Drug + polymer Observed Physical Appearance 
0 week 1 week 2 week 3 week 4 week 
1:5 1:5 1:5 1:5 1:5 
Drug Alone White Powder White Powder White Powder White Powder White Powder 
Drug+HPMC 
K15M+HPMC K100 
White Powder  White Powder White Powder White Powder White Powder 
 
FTIR: FTIR and DSC techniques were used to study the 
interaction between Drug and Polymer. FTIR spectrum of 
Omeprazole is shown in Fig 5.3 and it revealed various 
characteristic broad peaks such at 3416.30 cm in the spectra 
of the pure drug corresponds to C=N group. The peat at 
108.32 cm corresponding to C=S bonding. The peak at 
1610.83 per cm and 1571.37 per cm indicates the presence 
of carbonyl group. 
  
 
Fig 4: FTIR spectrum of Omeprazole 
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Fig: 5 FTIR spectrums of drug and HPMC K15M 
 
 
Fig: 6FTIR spectrum of drug and HPMC K100M 
 
DSC: DSC thermogram of Omeprazole showed a sharp 
endothermic peak at 182.6°C corresponding to the sharp 
melting point and representing its typical crystalline nature. 
Fig 5.7 shows the DSC thermogram of HPMC K100M with 
abroad peak at 162.1°C. Fig 5.8 shows the DSC thermogram 
of HPMC K15M with a broad peak at 163.0°C, attributed to 
desolation of water molecules. 
  
 
Fig: 7 DSC thermogram of Omeprazole 
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Fig: 8DSC thermogram of HPMC K 100M 
 
 
Fig: 9DSC thermogram of HPMC K15M 
 
Formulation and Evaluation Studies:  
We made a 9 batches of different concentration of polymer. 
In these batches the drug was 40 mg and polymer was taken 
as a mixture of HPMC K15M and HPMC K100M . We 
formulated a floating tablet by wet granulation method using 
isopropyl alcohol as a wetting agent. Excipients like 
magnesium stearate, PVPK30 and sodium bicarbonate in a 
dough were passed through sieve no. 40 and 60 then 
granules were dried in oven at 121°C for 1 hr. After properly 
drying of granules, then evaluate the pre compression 
parameters like bulk density , tap density , angle of repose. 
then punched the powder with punching machine and made 
500mg tablets. The post compression parameters like 
hardness, weight variation, friability, drug content, floating 
lag time, buoyancy time, dissolution time and disintegration 
time were calculated. F3batch has a greater % drug release 
91 %. 
  
Table 4: Preliminary batches using different polymer ratios concentration. 
S No. Batch Drug(mg.) HPMC 
K15M 
HPMC 
K100M 
PVP K30 Mag. 
Stearate 
Sod 
bicarbonates 
1 B1 40mg 10% - 4% 1% 10% 
2 B2 40mg 15% - 4% 1% 10% 
3 B3 40mg 20% - 4% 1% 10% 
4 B4 40mg - 10% 4% 1% 10% 
5 B5 40mg - 20% 4% 1% 10% 
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Table 5: Batches using mixture of polymers ratio: 
S. 
NO. 
Batch Omeprazole HPMC 
K100m 
(mg.) 
HPMC 
K15M 
(mg.) 
Lactose 
(mg.) 
Pvp   
K30 
(mg.) 
Mg. 
Stearate(mg.) 
Sodium 
Bicarbonate 
(mg.) 
1 F1 40 75 50 260 20 5 50 
2 F2 40 100 50 235 20 5 50 
3 F3 40 125 50 210 20 5 50 
4 F4 40 75 75 235 20 5 50 
5 F5 40 100 75 210 20 5 50 
6 F6 40 50 75 185 20 5 50 
7 F7 40 75 100 210 20 5 50 
8 F8 40 50 100 185 20 5 50 
9 F9 40 125 100 160 20 5 50 
 
Table 6: Results of % DR of preliminary batches of floating tablet 
 Hr. 
 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 1.22 2.55 5.32 9.32 6.9 13.62 10.25 9.35 6.35 
2 5.33 6.22 9.34 17.34 9.987 23.34 15.26 16.25 14.25 
3 8.55 10.25 13.45 24.66 14.23 43.88 18.33 25.16 18.65 
4 10.55 14.25 17.34 31.09 28.25 53.76 33.46 33.76 22.18 
6 16.00 15.26 23.65 48.39 37.77 59.29 44.34 46.33 37.85 
8 19.00 25.14 29.56 57.76 41.356 62.55 53.76 56.42 43.65 
11 25.56 26.05 39.25 64.86 44.83 72.73 59.11 64.71 51.26 
14 45.25 30.56 51.29 74.39 48.23 74.25 65.36 73.82 60.58 
17 53.68 42.277 62.54 78.76 56.82 75.99 73.82 83.71 68.54 
21 65.29 57.5 79.54 83.05 65.86 85.58 80.15 86.23 74.52 
24 85.25 75.5 91.25 90.56 82.79 89.26 86.85 88.95 80.23 
 
 
Fig 10: Dissolution profile of floating in Hcl pH 1.2 medium 
Zero order reaction: 
 
Fig: 11   zero order release of F3 formulation 
 
Fig: 12 first order release of formulation F-3 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
%
D
ru
g 
re
le
as
e
 
Times(hrs.) 
F1
F2
F3
F4
F5
F6
F7
F8
0
20
40
60
80
100
0 10 20 30
%
C
D
R
 
Times(hrs) 
Zero order reaction 
F3
Linear (F3)
0
0.5
1
1.5
2
2.5
0 5 10 15 20 25 30
%
C
D
R
 
Times(hrs) 
First order reaction 
F3
Linear (F3)
Kaushal et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):679-687 
ISSN: 2250-1177                                                                                   [687]                                                                                     CODEN (USA): JDDTAO 
 
Fig:13 Higuchi kinetics drug release formulation F-3 
 
Fig:14 Korsmeyer-peppas model of drug 
releasesformulation F3 
Table 6: Evaluation result of preliminary batches of 
floating tablet. 
Formulation FLT (S) BT (min) 
F1 78±0.07 578 ±0.51 
F2 103±0.10 596±0.42 
F3 159±0.12 581±0.67 
F4 197±0.08 697±0.17 
F5 232±0.12 706±0.78 
F6 268±0.09 718±0.41 
F7 284±0.11 789±0.12 
F8 306±0.07 809±0.14 
F9 347±0.17 814±0.09 
FLT-floating lag time and BT- buoyancy time* 
CONCLUSION 
The study conclusively demonstrated a floating tablet of 
Omeprazole, prepared using mixture of HPMC K15M and 
HPMC K100M as polymer, were successfully be prepared by 
wet granulation method which will lead to improved patient 
compliance and product quality. The technique adopted for 
the preparation of floating tablet was wet granulation. 
A comparative Omeprazole release study from pure drug and 
optimum batch in 0.IN HCL pH 1.2 was performed. It showed 
significant change in the percentage of Omeprazole released 
from floating tablet in HCL pH 1.2 medium was observed, 
which would affect its availability in stomach. 
When the optimum formulation was subjected to accelerated 
stability study at 40°C+2°C/75%RH±5%RH for three months 
it showed no significant change in the physical appearance, 
drug content and in vitro drug release characteristics, thus 
confirming stability we can conclude that:  
• Floating tablet were successfully prepared using wet 
granulation technique, and the resultant floating tablet 
showed the similar dissolution profile for the 
Omeprazole, release in acidic medium as that of the pure 
drug. 
• Since release of Omeprazole was increased from floating 
tablet in 0.1N HCL at 1.2 pH medium, therefore the 
retention time of Omeprazole is increased in stomach.  
• The FTIR, DSC and studies of the Omeprazole containing 
tablet indicated the phase inversion of Omeprazole from 
crystalline to amorphous form.  
• Floating tablet of Omeprazole prepared with mixture of 
HPMC K15M and HPMC K100M are better than the 
marketed tablet in case of patient compliance as increase 
retention time of drug in stomach.  
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